NCT04900038View on ClinicalTrials.gov

A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

PHASE2TerminatedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

August 18, 2021

Primary Completion Date

November 22, 2022

Study Completion Date

May 11, 2023

Conditions
HIV Infections
Interventions
DRUG

GSK3640254

GSK3640254 was available as 25 mg or 100 mg tablets administered orally.

DRUG

Dolutegravir

DTG was available as 50 mg tablets administered orally.

DRUG

Lamivudine capsules

3TC was available as 300 mg capsules administered orally as a blinded treatment.

DRUG

Lamivudine tablets

3TC was available as 300 mg tablets administered orally as an unblinded treatment.

Trial Locations (44)

1475

GSK Investigational Site, Vosloorus Ext 2

2113

GSK Investigational Site, Johannesburg

4091

GSK Investigational Site, Durban

7505

GSK Investigational Site, Parow

8003

GSK Investigational Site, Barcelona

10787

GSK Investigational Site, Berlin

20127

GSK Investigational Site, Milan

20146

GSK Investigational Site, Hamburg

24127

GSK Investigational Site, Bergamo

28007

GSK Investigational Site, Madrid

28031

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

30120

GSK Investigational Site, Murcia

32806

GSK Investigational Site, Orlando

33140

GSK Investigational Site, Miami

34982

GSK Investigational Site, Ft. Pierce

36312

GSK Investigational Site, Vigo

38320

GSK Investigational Site, La Laguna-Tenerife

46026

GSK Investigational Site, Valencia

48013

GSK Investigational Site, Bilbao

50668

GSK Investigational Site, Cologne

59208

GSK Investigational Site, Tourcoing

60596

GSK Investigational Site, Frankfurt am Main

64111

GSK Investigational Site, Kansas City

68198

GSK Investigational Site, Omaha

75012

GSK Investigational Site, Paris

80246

GSK Investigational Site, Denver

92262

GSK Investigational Site, Palm Springs

93301

GSK Investigational Site, Bakersfield

C1405CKC

GSK Investigational Site, Ciudad Autónoma de Buenos Aires

C1202ABB

GSK Investigational Site, Buenos Aires

C1425AGC

GSK Investigational Site, Buenos Aires

H2L 4E9

GSK Investigational Site, Montreal

H2L 4P9

GSK Investigational Site, Montreal

4369-004

GSK Investigational Site, Porto

4434-502

GSK Investigational Site, Vila Nova de Gaia

00909

GSK Investigational Site, San Juan

08036

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, Barcelona

?03203

GSK Investigational Site, Elche

07198

GSK Investigational Site, Palma de Mallorca

08830

GSK Investigational Site, Sant Boi de Llobregat

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

ViiV Healthcare

INDUSTRY